Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC):

Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III) is a phase 3, randomised interventional study registered as NCT06832917 by Wan He, with a registry enrolment figure of 238 participants, started 2025-03-31 and due to reach its primary completion in 2028-12-31. Interventions recorded: AK104 plus; Chemo only. Conditions listed: Rectal Cancer. Primary outcome: 3-year disease free survival (3-y DFS). Colorectal eligibility wording from the registry: "Histopathology confirmed the diagnosis of rectal adenocarcinoma". No results are recorded here; the registry entry is the source.